Anthropic Acquires Coeffiecient Bio for $400 Mn to Expand Footprint in AI-Driven Healthcare

The integration is expected to scale the development of AI-driven tools for research and clinical applications.

Anthropic has announced the acquisition of New York-based AI biotech startup Coefficient Bio at a deal valued at $400 million.

The acquisition is reported to be an all-stock transaction that aims to support Anthropic’s ongoing expansion into healthcare and life sciences.

Founded in 2025, the startup focuses on developing AI models to support biological research and improve efficiency in drug discovery processes. Its work includes enabling data-driven approaches to complex research challenges in biotechnology.

The deal follows Anthropic‘s earlier announcement of Claude for Life Sciences, designed to help scientific researchers in scientific discoveries and analysis.

In addition, the company has also introduced new capabilities for life sciences, with its offerings spanning preclinical R&D through clinical operations and regulatory affairs.

Following the acquisition, Coefficient Bio’s team is expected to join Anthropic’s healthcare and life sciences division.

The integration is expected to scale the development of AI-driven tools for research and clinical applications.

The company further aims to expand capabilities designed for complex biotech workflows, ranging from research planning and drug discovery to regulatory strategy.

Stay tuned for more such updates on Digital Health News